Mechanisms of Neuroprotection by Histone Deacetylase Inhibition

组蛋白脱乙酰酶抑制的神经保护机制

基本信息

  • 批准号:
    7461900
  • 负责人:
  • 金额:
    $ 34.13万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2008
  • 资助国家:
    美国
  • 起止时间:
    2008-03-01 至 2013-02-28
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The tumor suppressor p53 is recognized as an important regulator of apoptosis in acute and chronic neurological insults and neurodegenerative disorders. However, the downstream molecular consequences of p53 activation in neurons still remain obscure. Our proteomic analyses have demonstrated that DNA damage-induced neuronal apoptosis involves a p53-dependent increase in the expression of proteins that comprise histone deacetylase (HDAC) complexes. This data suggests that p53 might promote neuronal dysfunction/cell death by activating histone deacetylase activity. Our preliminary studies indeed demonstrate that histone deacetylase inhibitors protect against p53-mediated cell death. In contrast HDAC activity is generally elevated in cancer cells, and HDAC inhibition actually induces p53-dependent cell death. In the present application, based on this novel finding of the neuron-specific mode of HDAC inhibitor actions, we propose to test the hypothesis that p53-mediated cell death signaling in neurons is dependent on histone deacetylase activity by examining how HDAC inhibitors block neuronal cell death. We will specifically: 1) Determine if HDAC inhibitors selectively protect neurons from p53-mediated cell death, 2) Determine if HDAC inhibitors directly block p53 activation and/or transcriptional activity required for p53-dependent cell death in neurons; and 3) Determine if HDAC inhibitors prevent p53- dependent changes in mitochondrial integrity. The aims of this proposal will help us to better understand the molecular sites and mechanism of HDAC inhibitor action, which will enhance the utility of these inhibitors as therapeutic agents for neurological diseases and injury. PUBLIC HEALTH RELEVANCE: Histone deacetylase inhibitors protect neurons from dying in several mouse models of human neurodegenerative disease. However, the mechanism by which histone deacetylase inhibitors prevent cell death is not understood. A better understanding of how these compounds work and the types of diseases or injuries that they protect against would enhance their range of action and their effectiveness. We propose to determine how histone deacetylase inhibitors block neuronal cell death which could lead to the development of new therapeutic agents for treating neurological diseases and nervous system injury.
描述(由申请人提供):肿瘤抑制因子p53被认为是急性和慢性神经损伤和神经退行性疾病中细胞凋亡的重要调节因子。然而,神经元中p53激活的下游分子后果仍然不清楚。我们的蛋白质组学分析表明,DNA损伤诱导的神经元凋亡涉及p53依赖性增加的蛋白质,包括组蛋白脱乙酰酶(HDAC)复合物的表达。这些数据表明,p53可能通过激活组蛋白去乙酰化酶活性促进神经元功能障碍/细胞死亡。我们的初步研究确实表明,组蛋白去乙酰化酶抑制剂防止p53介导的细胞死亡。相反,HDAC活性在癌细胞中通常升高,并且HDAC抑制实际上诱导p53依赖性细胞死亡。在本申请中,基于HDAC抑制剂作用的神经元特异性模式的这一新发现,我们提出通过检查HDAC抑制剂如何阻断神经元细胞死亡来检验神经元中p53介导的细胞死亡信号传导依赖于组蛋白脱乙酰酶活性的假设。我们将具体:1)确定HDAC抑制剂是否选择性地保护神经元免于p53介导的细胞死亡,2)确定HDAC抑制剂是否直接阻断神经元中p53依赖性细胞死亡所需的p53激活和/或转录活性;和3)确定HDAC抑制剂是否防止线粒体完整性中的p53依赖性变化。该建议的目的将有助于我们更好地了解HDAC抑制剂作用的分子位点和机制,这将增强这些抑制剂作为神经系统疾病和损伤的治疗剂的效用。 公共卫生相关性:组蛋白去乙酰化酶抑制剂在几种人类神经退行性疾病小鼠模型中保护神经元免于死亡。然而,组蛋白去乙酰化酶抑制剂防止细胞死亡的机制尚不清楚。更好地了解这些化合物的工作原理以及它们预防的疾病或伤害类型将扩大它们的作用范围和有效性。我们建议确定组蛋白去乙酰化酶抑制剂如何阻断神经元细胞死亡,这可能导致开发新的治疗药物用于治疗神经系统疾病和神经系统损伤。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

RICHARD S MORRISON其他文献

RICHARD S MORRISON的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('RICHARD S MORRISON', 18)}}的其他基金

Functional characterization of the Bax-interacting factor-1 interactome in neurons
神经元中 Bax 相互作用因子 1 相互作用组的功能表征
  • 批准号:
    9475333
  • 财政年份:
    2017
  • 资助金额:
    $ 34.13万
  • 项目类别:
Functional characterization of the Bax-interacting factor-1 interactome in neurons
神经元中 Bax 相互作用因子 1 相互作用组的功能表征
  • 批准号:
    9387154
  • 财政年份:
    2017
  • 资助金额:
    $ 34.13万
  • 项目类别:
A transgenic model to study Bif-1 mediated neuroprotection in injury and disease
研究 Bif-1 介导的损伤和疾病神经保护的转基因模型
  • 批准号:
    8694930
  • 财政年份:
    2014
  • 资助金额:
    $ 34.13万
  • 项目类别:
A transgenic model to study Bif-1 mediated neuroprotection in injury and disease
研究 Bif-1 介导的损伤和疾病神经保护的转基因模型
  • 批准号:
    8815342
  • 财政年份:
    2014
  • 资助金额:
    $ 34.13万
  • 项目类别:
Histone deacetylases - therapeutic targets for functional restoration after strok
组蛋白脱乙酰酶 - 中风后功能恢复的治疗靶点
  • 批准号:
    8048964
  • 财政年份:
    2010
  • 资助金额:
    $ 34.13万
  • 项目类别:
Histone deacetylases - therapeutic targets for functional restoration after strok
组蛋白脱乙酰酶 - 中风后功能恢复的治疗靶点
  • 批准号:
    8243635
  • 财政年份:
    2010
  • 资助金额:
    $ 34.13万
  • 项目类别:
Histone deacetylases - therapeutic targets for functional restoration after strok
组蛋白脱乙酰酶 - 中风后功能恢复的治疗靶点
  • 批准号:
    8440328
  • 财政年份:
    2010
  • 资助金额:
    $ 34.13万
  • 项目类别:
Histone deacetylases - therapeutic targets for functional restoration after strok
组蛋白脱乙酰酶 - 中风后功能恢复的治疗靶点
  • 批准号:
    8634140
  • 财政年份:
    2010
  • 资助金额:
    $ 34.13万
  • 项目类别:
Histone deacetylases - therapeutic targets for functional restoration after strok
组蛋白脱乙酰酶 - 中风后功能恢复的治疗靶点
  • 批准号:
    7899421
  • 财政年份:
    2010
  • 资助金额:
    $ 34.13万
  • 项目类别:
NINDS INSTITUTIONAL CENTER CORE GRANTS - Neuroproteomics P30
NINDS 机构中心核心资助 - 神经蛋白质组学 P30
  • 批准号:
    8116685
  • 财政年份:
    2008
  • 资助金额:
    $ 34.13万
  • 项目类别:

相似海外基金

Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
  • 批准号:
    MR/Y009568/1
  • 财政年份:
    2024
  • 资助金额:
    $ 34.13万
  • 项目类别:
    Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
  • 批准号:
    10090332
  • 财政年份:
    2024
  • 资助金额:
    $ 34.13万
  • 项目类别:
    Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
  • 批准号:
    MR/X02329X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 34.13万
  • 项目类别:
    Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
  • 批准号:
    MR/X021882/1
  • 财政年份:
    2024
  • 资助金额:
    $ 34.13万
  • 项目类别:
    Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
  • 批准号:
    MR/X029557/1
  • 财政年份:
    2024
  • 资助金额:
    $ 34.13万
  • 项目类别:
    Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
  • 批准号:
    EP/Y003527/1
  • 财政年份:
    2024
  • 资助金额:
    $ 34.13万
  • 项目类别:
    Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
  • 批准号:
    EP/Y030338/1
  • 财政年份:
    2024
  • 资助金额:
    $ 34.13万
  • 项目类别:
    Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
  • 批准号:
    2312694
  • 财政年份:
    2024
  • 资助金额:
    $ 34.13万
  • 项目类别:
    Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
  • 批准号:
    24K19395
  • 财政年份:
    2024
  • 资助金额:
    $ 34.13万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
  • 批准号:
    484000
  • 财政年份:
    2023
  • 资助金额:
    $ 34.13万
  • 项目类别:
    Operating Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了